CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 52963-53133 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T47296","span":{"begin":0,"end":170},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moderate to large effect sizes in the omalizumab groups were maintained throughout the 28-week clinical trial program and during the 24-week double-blind extension phase."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T32","span":{"begin":0,"end":170},"obj":"Sentence"}],"text":"Moderate to large effect sizes in the omalizumab groups were maintained throughout the 28-week clinical trial program and during the 24-week double-blind extension phase."}

    CORD-19-PD-UBERON

    {"project":"CORD-19-PD-UBERON","denotations":[{"id":"T133","span":{"begin":154,"end":163},"obj":"Body_part"}],"attributes":[{"id":"A133","pred":"uberon_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/UBERON_2000106"}],"text":"Moderate to large effect sizes in the omalizumab groups were maintained throughout the 28-week clinical trial program and during the 24-week double-blind extension phase."}